MA34064B1 - Compose heterocyclique - Google Patents

Compose heterocyclique

Info

Publication number
MA34064B1
MA34064B1 MA35205A MA35205A MA34064B1 MA 34064 B1 MA34064 B1 MA 34064B1 MA 35205 A MA35205 A MA 35205A MA 35205 A MA35205 A MA 35205A MA 34064 B1 MA34064 B1 MA 34064B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compound
component
salt
relates
useful
Prior art date
Application number
MA35205A
Other languages
Arabic (ar)
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34064(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of MA34064B1 publication Critical patent/MA34064B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

L'INVENTION PORTE SUR UN COMPOSÉ UTILE EN TANT QU'AGENT PROPHYLACTIQUE OU THÉRAPEUTIQUE POUR LE CANCER. PLUS PARTICULIÈREMENT, L'INVENTION PORTE SUR UN COMPOSÉ REPRÉSENTÉ PAR LA FORMULE (I) [CHAQUE SYMBOLE ÉTANT TEL QUE DÉFINI DANS LA DESCRIPTION] OU SUR UN SEL DE CELUI-CI, OU SUR UN PROMÉDICAMENT DU COMPOSÉ OU DU SEL DE CELUI-CI, UTILE POUR LA PRÉVENTION OU LE TRAITEMENT DU CANCER.
MA35205A 2010-02-17 2011-02-16 Compose heterocyclique MA34064B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09
PCT/JP2011/053303 WO2011102399A1 (fr) 2010-02-17 2011-02-16 Composé hétérocyclique

Publications (1)

Publication Number Publication Date
MA34064B1 true MA34064B1 (fr) 2013-03-05

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
MA35205A MA34064B1 (fr) 2010-02-17 2011-02-16 Compose heterocyclique

Country Status (37)

Country Link
US (6) US8722660B2 (fr)
EP (2) EP3533797B1 (fr)
JP (1) JP5689454B2 (fr)
KR (1) KR101735868B1 (fr)
CN (1) CN102844320B (fr)
AU (1) AU2011216404B2 (fr)
BR (1) BR112012020311B1 (fr)
CA (1) CA2790284C (fr)
CL (1) CL2012002250A1 (fr)
CO (1) CO6592104A2 (fr)
CR (1) CR20120448A (fr)
CY (1) CY1121792T1 (fr)
DK (1) DK2540728T3 (fr)
DO (1) DOP2012000224A (fr)
EA (1) EA020724B1 (fr)
EC (1) ECSP12012160A (fr)
ES (1) ES2733221T3 (fr)
GE (1) GEP20146202B (fr)
HR (1) HRP20190947T1 (fr)
HU (1) HUE043514T2 (fr)
IL (1) IL221442A0 (fr)
LT (1) LT2540728T (fr)
MA (1) MA34064B1 (fr)
ME (1) ME03410B (fr)
MX (1) MX353500B (fr)
MY (1) MY164776A (fr)
NZ (1) NZ602089A (fr)
PE (1) PE20130184A1 (fr)
PH (1) PH12012501650B1 (fr)
PL (1) PL2540728T3 (fr)
PT (1) PT2540728T (fr)
RS (1) RS58796B1 (fr)
SG (1) SG183304A1 (fr)
SI (1) SI2540728T1 (fr)
SM (1) SMT201900385T1 (fr)
TN (1) TN2012000401A1 (fr)
WO (1) WO2011102399A1 (fr)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12013500274A1 (en) * 2010-08-11 2013-03-04 Millennium Pharm Inc Heteroaryls and uses thereof
JP6569908B2 (ja) 2014-01-31 2019-09-04 カルナバイオサイエンス株式会社 抗がん剤組成物
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
EP3387571B1 (fr) 2015-12-07 2021-03-31 Zymergen, Inc. Amélioration de souches microbiennes par une plateforme d'ingénierie génomique htp
EP3394056B1 (fr) 2015-12-22 2021-04-14 Shy Therapeutics LLC Composés pour le traitement du cancer et de maladies inflammatoires
US11746109B2 (en) * 2016-03-28 2023-09-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one hemihydrate
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
US11020396B2 (en) 2016-11-08 2021-06-01 Cancer Research Technology Limited Pyrimidinone derivatives as Cdc7 inhibitors
WO2018158898A1 (fr) 2017-03-01 2018-09-07 Takeda Pharmaceutical Company Limited Procédé de prédiction des effets d'un inhibiteur de cdc7
CN110381950B (zh) * 2017-05-21 2020-09-04 南京正济医药研究有限公司 作为抗癌剂的取代的[5,6]环-4(3h)-嘧啶酮
CA3066939A1 (fr) 2017-06-21 2018-12-27 SHY Therapeutics LLC Composes interagissant avec la superfamille ras destines a etre utilises dans le traitement de cancers, de maladies inflammatoires, de rasopathies et de maladies fibrotiques
EP3774816A1 (fr) * 2018-04-02 2021-02-17 Takeda Pharmaceutical Company Limited Procédés de synthèse de 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-méthyl-1 h-pyrazol-4-yl)thiéno[3,2-d]pyrimidin-4(3h)-one
TWI846703B (zh) 2018-06-19 2024-07-01 日商武田藥品工業股份有限公司 癌症治療方法
EP3823599B1 (fr) * 2018-07-19 2024-08-28 Takeda Pharmaceutical Company Limited Compositions pharmaceutiques comprenant un inhibiteur de cdc7
US12533353B2 (en) 2018-09-24 2026-01-27 Carna Biosciences, Inc. Methods of treatment of cancer comprising CDC7 inhibitors
US12391705B2 (en) 2018-12-19 2025-08-19 Shy Therapeutics, Llc Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
AU2020281411A1 (en) * 2019-05-30 2022-01-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compounds as Cdc7 inhibitors
BR112022000734A2 (pt) * 2019-07-19 2022-04-12 Takeda Pharmaceuticals Co Método para tratar câncer em um paciente, uso de composto 1, e, composto 1
US20220389026A1 (en) * 2019-08-20 2022-12-08 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compound used as cdc7 inhibitor
WO2021113492A1 (fr) 2019-12-06 2021-06-10 Schrödinger, Inc. Composés cycliques et leurs procédés d'utilisation
CN116490507A (zh) * 2020-09-10 2023-07-25 薛定谔公司 用于治疗癌症的杂环包缩合cdc7激酶抑制剂
WO2022111729A1 (fr) * 2020-11-30 2022-06-02 正大天晴药业集团股份有限公司 Forme de sel utilisée en tant qu'inhibiteur de cdc7 et forme cristalline de celui-ci
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
JP2024506314A (ja) * 2021-02-08 2024-02-13 武田薬品工業株式会社 がん治療のための併用療法
CN117120447A (zh) * 2021-03-18 2023-11-24 薛定谔公司 环状化合物和其使用方法
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
WO2023064879A1 (fr) * 2021-10-13 2023-04-20 Remix Therapeutics Inc. Composés et procédés de modulation de l'épissage d'acides nucléiques
WO2025160538A1 (fr) * 2024-01-26 2025-07-31 The Board Of Regents Of The University Of Texas System Compositions et méthodes de traitement du grisonnement et de la chute des cheveux associés au vieillissement
WO2025168620A1 (fr) 2024-02-07 2025-08-14 Bayer Aktiengesellschaft 4,5-dihydro-1h-2,4,5-oxadiazines substituées par hétéroaryle utilisées en tant que nouveaux fongicides

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA782648B (en) * 1977-05-23 1979-06-27 Ici Australia Ltd The prevention,control or eradication of infestations of ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
CA2423981A1 (fr) 2000-09-29 2003-03-28 Kimiko Ichikawa Composes de thienopyrimidine et leurs sels et procede de preparation
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
WO2002085909A1 (fr) 2001-04-20 2002-10-31 Vertex Pharmaceuticals Incorporated Derives de 9-deazaguanine utilises comme inhibiteurs de la gsk-3
DE60304718T2 (de) 2002-08-06 2007-04-26 Astrazeneca Ab Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
EP1646615B1 (fr) 2003-06-06 2009-08-26 Vertex Pharmaceuticals Incorporated Derives de pyrimidne utilises en tant que modulateurs de transporteurs de cassette de liaison a l'atp
DE602004020070D1 (de) * 2003-06-11 2010-10-07 Xention Ltd Thienopyrimidin-derivate als kaliumkanal-inhibitoren
US20050032869A1 (en) * 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
DE602004014163D1 (de) 2003-08-08 2008-07-10 Pfizer Italia Srl Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
RU2006138036A (ru) * 2004-03-30 2008-05-10 Чирон Корпорейшн (Us) Производные замещенного тиофена в качестве противораковых средств
US8193332B2 (en) 2004-04-09 2012-06-05 Genecare Research Institute Co., Ltd. Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
US20080102068A1 (en) 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
US20080221107A1 (en) 2005-07-15 2008-09-11 Astrazeneca Ab Therapeutic Agents
AU2006285915B2 (en) 2005-08-30 2011-02-24 Asahi Kasei Pharma Corporation Sulfonamide compound
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) * 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
WO2007102679A1 (fr) 2006-03-06 2007-09-13 Je Il Pharmaceutical Co., Ltd. Nouveaux dérivés de la thiénopyrimidine ou leurs sels pharmacocompatibles, leur procédé de préparation, et préparations pharmaceutiques les comprenant
WO2008082839A2 (fr) 2006-12-29 2008-07-10 Abbott Laboratories Inhibiteurs de la pim kinase comme agents chimiothérapeutiques destinés à lutter contre le cancer
US20090030196A1 (en) * 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
CL2008000252A1 (es) 2007-01-29 2008-03-14 Xenon Pharmaceuticals Inc Compuestos derivados de quinazolinona o pirimidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades mediadas por los canales de calcio, tales como dolor, depresion, enfermedades cardiovasculares, respir
WO2009001214A2 (fr) 2007-06-28 2008-12-31 Pfizer Products Inc. Dérivés de thieno[2,3-d]pyrimidin-4(3h)-one, d'isoxazolo[5,4-d]pyrimidin-4(5h)-one et d'isothiazolo[5,4-d]pyrimidin-4(5h)-one utilisés comme antagonistes du récepteur du calcium
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
MX2010014280A (es) 2008-06-26 2011-05-23 Dana Farber Cancer Inst Inc Distintivos y determinantes asociados con metástasis y método para utilizarlos.
WO2010101302A1 (fr) 2009-03-05 2010-09-10 Takeda Pharmaceutical Company Limited Thiénopyrimidines en tant qu'inhibiteurs de la kinase cdc7
WO2010126002A1 (fr) 2009-04-28 2010-11-04 塩野義製薬株式会社 Produit pharmaceutique contenant un composé sulfonamide hétérocyclique
US20120238533A1 (en) 2009-09-11 2012-09-20 Bayer Pharma Aktiengesellschaft (Heteroarylmethyl) Thiohydantoins as anticancer drugs
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
US20140228352A1 (en) 2014-08-14
PE20130184A1 (es) 2013-03-09
SMT201900385T1 (it) 2019-09-09
US8921354B2 (en) 2014-12-30
EP3533797A1 (fr) 2019-09-04
ES2733221T3 (es) 2019-11-28
US9388195B2 (en) 2016-07-12
CY1121792T1 (el) 2020-07-31
SI2540728T1 (sl) 2019-06-28
US20160310494A1 (en) 2016-10-27
NZ602089A (en) 2014-05-30
US20130029969A1 (en) 2013-01-31
EP2540728B1 (fr) 2019-04-10
TN2012000401A1 (en) 2014-01-30
EP2540728A1 (fr) 2013-01-02
MY164776A (en) 2018-01-30
MX353500B (es) 2018-01-16
PH12012501650B1 (en) 2018-11-07
EP2540728A4 (fr) 2013-11-06
PT2540728T (pt) 2019-07-11
AU2011216404B2 (en) 2016-04-07
JP5689454B2 (ja) 2015-03-25
CR20120448A (es) 2012-11-13
SG183304A1 (en) 2012-09-27
EA020724B1 (ru) 2015-01-30
AU2011216404A1 (en) 2012-09-20
MX2012009602A (es) 2012-12-17
BR112012020311A2 (pt) 2017-03-01
CN102844320B (zh) 2016-03-23
IL221442A0 (en) 2012-10-31
US20170209452A1 (en) 2017-07-27
GEP20146202B (en) 2014-11-25
CA2790284C (fr) 2019-01-08
US20150158882A1 (en) 2015-06-11
LT2540728T (lt) 2019-06-25
RS58796B1 (sr) 2019-07-31
CN102844320A (zh) 2012-12-26
EA201290800A1 (ru) 2013-03-29
DK2540728T3 (da) 2019-05-13
EP3533797B1 (fr) 2023-12-20
US9655900B2 (en) 2017-05-23
CA2790284A1 (fr) 2011-08-25
KR20130001246A (ko) 2013-01-03
BR112012020311B1 (pt) 2019-01-29
ECSP12012160A (es) 2013-03-28
PH12012501650A1 (en) 2012-10-22
US8933069B2 (en) 2015-01-13
ME03410B (fr) 2020-01-20
US8722660B2 (en) 2014-05-13
CO6592104A2 (es) 2013-01-02
WO2011102399A1 (fr) 2011-08-25
HRP20190947T1 (hr) 2019-07-26
CL2012002250A1 (es) 2013-02-08
JPWO2011102399A1 (ja) 2013-06-17
KR101735868B1 (ko) 2017-05-15
DOP2012000224A (es) 2013-01-31
HUE043514T2 (hu) 2019-08-28
US20140235615A1 (en) 2014-08-21
PL2540728T3 (pl) 2019-09-30

Similar Documents

Publication Publication Date Title
MA34064B1 (fr) Compose heterocyclique
PH12017502141A1 (en) Compounds and their methods of use
EA201391626A1 (ru) Соединения для ингибирования клеточной пролиферации в egfr-стимулированных типах рака
EA201071032A1 (ru) Гетероциклическое соединение
MX352672B (es) Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
MX374513B (es) Compuestos de morfolinona de ácido heteroarilo como inhibidores mdm2 para el tratamiento de cáncer.
MX2016000675A (es) Derivados de amino-metil-biarilo como inhibidores del factor de complemento d y usos de los mismos.
UA111161C2 (uk) Похідна фталазинонкетону, спосіб її одержання та її фармацевтичне застосування
PH12016500072B1 (en) Piperidinyl-indole derivatives complement factor b inhibitors and uses thereof
TN2012000559A1 (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
PH12015501316A1 (en) Heterocyclic compound
EA201690598A1 (ru) Аминогетероарил бензамиды в качестве ингибиторов киназы
GEP201706624B (en) Triazolopyrazine as brd4 inhibitors and usage thereof for cancer treatment
TN2013000413A1 (en) Glycoside derivatives and their uses for the treatment of diabetes
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MY183327A (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2013007937A (es) Nuevo derivado de indol o indazol o sal del mismo.
NZ700356A (en) Pyrazole compounds as sglt1 inhibitors
EA201270728A1 (ru) Пуриновые соединения
UA110834C2 (uk) Сполука-інгібітор сигнального шляху notch
TN2010000397A1 (en) Heterocyclic compounds
MX2011003390A (es) Compuestos y composiciones útiles en el tratamiento de enfermedades cardiacas con efectos secundarios reducidos.